The benefits of lowering low-density lipoprotein (LDL) cholesterol with statin therapy for cardiovascular disease (CVD) prevention are well established. Recent guidelines from the National Institute for Health and Clinical Excellence (NICE) have emphasised the importance of achieving lower lipid levels, by adopting targets of 4 mmol/L for total cholesterol and 2 mmol/L for LDL cholesterol as defined by the Joint British Societies’ 2 (JBS 2) guidelines in people with, or at high risk for, CVD, including those with type 2 diabetes.
